首页> 外文期刊>Molecular and Cellular Biochemistry: An International Journal for Chemical Biology >Enhanced P-selectin expression on platelet-a marker of platelet activation, in young patients with angiographically proven coronary artery disease
【24h】

Enhanced P-selectin expression on platelet-a marker of platelet activation, in young patients with angiographically proven coronary artery disease

机译:血管造影证实的年轻冠状动脉疾病患者中血小板上P选择素的表达增强-血小板活化的标志

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

P-selectin (CD62p) exposure is an established marker for platelet activation. P-selectin exposure can trigger variety of thrombotic and inflammatory reactions. In patients with coronary artery disease (CAD), platelets are activated, and hence, there is increased P-selectin exposure. The role of P-selectin exposure in patients on treatment with statins and anti-platelets is conflicting. A case-control study was performed to determine P-selectin exposure in consecutively recruited 142 patients (age aecurrency sign 55 years) with angiographically proven CAD on treatment and 92 asymptomatic controls. P-selectin exposure was determined by flow cytometry. Data on conventional risk factors were obtained along with estimation of levels of thrombotic [fibrinogen, lipoprotein (a), tissue plasminogen activator, plasminogen activator inhibitor-1, homocysteine and von Willebrand factor] and anti-thrombotic factors (antithrombin III). The P-selectin exposure was compared among patient groups who had different modes of presentation of CAD and categories of CAD disease severity. The patients were followed up for a period of 26 months. The results indicate that P-selectin exposure was significantly elevated in patients (mean +/- SD 9.24 +/- 11.81) compared to controls (mean +/- SD 1.48 +/- 2.85) with p < 0.0001. Similarly, conventional risk factors were significantly elevated in patients. P-selectin exposure showed significant negative correlation with antithrombin III levels. P-selectin exposure was higher in patients who presented with acute coronary syndromes than those who presented with effort angina. Cardiovascular event rate was 6 % on follow-up. The study establishes that thrombotic-inflammatory pathways enhancing P-selectin exposure unrelated to treatment might be activated in patients, while the event rate remained lowered, and hence, treatment strategies should be inclusive to control these factors.
机译:P选择素(CD62p)暴露是血小板活化的既定标志物。 P-选择素暴露会触发各种血栓形成和炎症反应。在患有冠状动脉疾病(CAD)的患者中,血小板被激活,因此P-选择素暴露增加。 P-选择素暴露于患者接受他汀类药物和抗血小板治疗的作用是矛盾的。进行了一项病例对照研究,以确定连续入选的142例经血管造影证实为治疗的CAD患者和92例无症状对照的患者(年龄现征55岁)中的P-选择素暴露。通过流式细胞术确定P-选择素暴露。获得有关常规危险因素的数据以及血栓形成水平的估计值[纤维蛋白原,脂蛋白(a),组织纤溶酶原激活物,纤溶酶原激活物抑制剂-1,同型半胱氨酸和血管性血友病因子]和抗血栓形成因子(抗凝血酶III)。比较了具有不同表现形式和不同CAD疾病严重程度的患者组中的P-选择素暴露。对患者进行了26个月的随访。结果表明,与对照组(平均值+/- SD 1.48 +/- 2.85)相比,患者的P-选择素暴露显着升高(平均值+/- SD 9.24 +/- 11.81),p <0.0001。同样,患者的常规危险因素也明显升高。 P-选择素暴露与抗凝血酶III水平显着负相关。患有急性冠状动脉综合征的患者的P-选择素暴露水平高于具有努力型心绞痛的患者。随访时心血管事件发生率为6%。该研究确定,与治疗无关的增强P-选择素暴露的血栓性炎症途径可能在患者中被激活,而事件发生率仍然降低,因此,治疗策略应包括在内以控制这些因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号